The estimated Net Worth of Kevin Woods is at least $1.96 Million dollars as of 6 November 2003. Kevin Woods owns over 30,000 units of Icad Inc stock worth over $1,801,286 and over the last 21 years Kevin sold ICAD stock worth over $158,100.
Kevin has made over 1 trades of the Icad Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Kevin sold 30,000 units of ICAD stock worth $158,100 on 6 November 2003.
The largest trade Kevin's ever made was selling 30,000 units of Icad Inc stock on 6 November 2003 worth over $158,100. On average, Kevin trades about 30,000 units every 0 days since 2003. As of 6 November 2003 Kevin still owns at least 1,295,889 units of Icad Inc stock.
You can see the complete history of Kevin Woods stock trades at the bottom of the page.
Kevin's mailing address filed with the SEC is 4 TOWNSEND WEST, SUITE 17, NASHUA, NH, 03063.
Over the last 22 years, insiders at Icad Inc have traded over $10,970,060 worth of Icad Inc stock and bought 704,596 units worth $1,672,448 . The most active insiders traders include Anthony F Ecock, Nathaniel Dalton, and Kevin C Burns. On average, Icad Inc executives and independent directors trade stock every 45 days with the average trade being worth of $39,056. The most recent stock trade was executed by Dana R Brown on 31 March 2023, trading 40,000 units of ICAD stock currently worth $52,000.
icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.
Icad Inc executives and other stock owners filed with the SEC include: